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An important difference between placental mammals and marsupials is the maturity of the fetus at birth.
Placental mammals achieved this maturity by developing a complex and invasive placenta to support and
prolong internal development. The exact genomic modifications that facilitated the evolution of this complex
structure are unknown, but the emergence of genomic imprinting within mammalian lineages suggests a role
for gene dosage. Here we show that a maximally altered placental structure is achieved by a single extra dose
of the imprinted Phlda2 gene characterized by a dramatically reduced junctional zone and a decrease in stored
glycogen. In addition, glycogen cells do not migrate into the maternal decidua in a timely fashion, but instead,
Tpbpa-positive cells progressively mislocalize into the labyrinth. These defects are linked to a progressive
restriction of embryonic growth from embryonic day 16.5. This work has identified a critical role for the
imprinted Phlda2 gene in regulating glycogen storage in the eutherian placenta and implies that imprinting has
provided a mechanism to boost nutrient supply to the fetus late in gestation, when the fetus is placing the
highest demands on maternal resources, to enhance growth.
Distinct to mammals, embryonic growth is dependent on
the ability of the mother to support in utero growth. The
choriovitelline placenta initially provides access to maternal
nutrients, and, as the demands of fetal growth increase,
monotremes and marsupials remain dependent on the yolk sac
placenta but eutherian mammals switch to an elaborate cho-
rioallantoic placenta (22, 43). Very few genes are expressed
uniquely in the placenta. The majority have arisen from exist-
ing genes by means of placenta-specific promoters, from the
duplication of large gene families, or through the adoption of
functions associated with endogenous retroviruses and retro-
elements (42). A surprising number of imprinted gene knock-
out models exhibit placental defects (19), suggesting gene dos-
age as another mechanism important in the evolution of the
fetoplacental unit. Approximately 0.3% of autosomal genes
are imprinted in eutherian mammals, while a subset of these
genes are imprinted in marsupials with no evidence of imprint-
ing in other vertebrates (1, 31, 32, 37, 39, 51, 54, 56, 58). Thus,
the emergence of genomic imprinting coincides with the ap-
pearance of extraembryonic support, and, as the demands for
this support have increased, the number of imprinted genes
co-opted by the imprinting mechanism has increased (30), also
suggesting the involvement of these unique genes in placental
development.
The mouse placenta is organized into the histologically dis-
tinct labyrinth zone, junctional zone, giant cell layer, and ma-
ternal decidua (9–11, 27, 45, 49). The giant cells are thought to
modify the maternal uterine vasculature, promoting maternal
blood flow toward the implantation site, while in the labyrinth
zone exchange takes place between the maternal and fetal
circulation. The junctional zone, also known as the spongio-
trophoblast layer, provides a source of pregnancy-related hor-
mones (9, 35), but, although this layer is absolutely required
for embryonic survival (25, 26), its function is less well under-
stood. It is composed of two major cell types, spongiotropho-
blast and glycogen cells, which both express trophoblast-spe-
cific protein alpha (Tpbpa), with the glycogen cells additionally
accumulating glycogen within their cytoplasm from embryonic
day 12.5 (E12.5) (5, 9). An unusual feature of glycogen cells is
their migration into the maternal decidua late in gestation,
where they may function to provide a rapidly mobilizable en-
ergy source during late pregnancy and parturition. Despite the
amazing variety in the forms and types of eutherian placenta,
easily detectable stores of glycogen are a common feature (8).
Imprinted genes located at mouse distal chromosome 7 play
an important role in regulating embryonic and placental growth
(16, 38). With regard to imprinting, this chromosomal region
can be separated mechanistically into two distinct domains (7).
Each domain contains one key gene that directly modulates
embryonic growth. The IC1 domain contains the gene for the
potent embryonic growth factor insulin-like growth factor 2
(Igf2) (13, 14). Global loss of expression of Igf2 directly limits
embryonic growth, while Igf2 deficiency localized to the pla-
centa indirectly restricts embryonic growth (12). The predicted
consequence of imprinting Igf2 (reduced dosage) would be to
limit embryonic growth. Cyclin-dependent kinase inhibitor 1C
(Cdkn1c) is the major regulator of embryonic growth within
the adjacent IC2 domain (2). In contrast to Igf2, imprinting of
Cdkn1c would be predicted to enhance embryonic growth.
Pleckstrin homology-like domain family A member 2 (Phlda2)
and achaete-scute complex homolog 2 (Ascl2) also map to the
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IC2 region (24, 41) but primarily play a role in extraembryonic
development. Ascl2 deficiency results in embryonic lethality
at midgestation due to placental failure, but tetraploid rescue
experiments exclude a direct role in regulating embryonic
growth or adult development (25, 26, 53). Phlda2 is also predom-
inantly expressed in the placenta from the maternal allele being
expressed in syncytiotrophoblast layers II and III of the laby-
rinth (15, 21, 41). Phlda2 deficiency results in placentomegaly
with a specific increase in the area of the junctional zone but
with no overt consequence for embryonic growth or adult de-
velopment (20).
A mouse model of loss of imprinting of the IC2 domain, in
which several imprinted genes are overexpressed, shows pla-
cental stunting (17) and a reduction of the junctional zone
(46). We previously showed, indirectly, that Phlda2 rescues the
volume of the junctional zone by normalizing Phlda2 expres-
sion in these Kvdmr1/ mice. We also showed that excess
dosage of the region spanning Phlda2 and a second imprinted
gene, the solute carrier family 22 member 18 gene (Slc22a18),
restricts placental growth and noted a subtle and late embry-
onic growth restriction phenotype (46). In our transgenic
model the two imprinted genes were overexpressed at high
levels from three copies of a bacterial artificial chromosome
(BAC), suggesting misregulated expression. Given the impor-
tance of the junctional zone in embryonic viability and the
potential role of PHLDA2 in human intrauterine growth re-
striction (IUGR) (36), we sought to perform a more detailed
characterization of the consequence of excess expression of
Phlda2 and Slc22a18 in three independent transgenic lines with
increasing doses of the transgene and in two genetic back-
grounds. Using a single-copy transgene, we asked whether nor-
malizing Phlda2 expression rescued the identified phenotypes,
which included a unique mislocalization defect. Finally, we
characterized embryonic growth from E13.5 to E18.5 in two
independent lines. We identify critical roles for Phlda2 in reg-
ulating glycogen storage and in coordinating the location of
spongiotrophoblast and glycogen cells late in gestation.
MATERIALS AND METHODS
Mouse strains and genotyping. All animal studies and breeding were approved
by the Universities of Cardiff ethical committee and performed under a UK
Home Office project license (R.M.J.). Lines 10-15, 5D3, and Phlda2/ were
previously described (20, 29). Transgenic line 10-10 was newly generated as
described for line 10-15 (29). In addition to Phlda2 and Slc22a18, the BAC
transgene spans a third gene, Cdkn1c, which is inactivated by insertion of lacZ in
lines 10-15 and 10-10 but not in line 5D3. The BAC does not imprint (29), and
experimental material was generated by male transmission. A small portion of
the tail tip or ear pinnae was removed between postnatal day 7 (P7) and P14 and
genotyped as described previously (20, 29).
Weighing studies. Embryonic and placental wet weights were taken at the
stated time points after the formation of a discernible plug. Genotyping data was
obtained from yolk sac DNA as described or by staining for the lacZ reporter as
described previously (20, 29).
mRNA analysis. Quantitative PCR of reverse-transcribed RNA (QRT-PCR)
was performed as described previously (2). For the additional primers used see
Table S3 in the supplemental material. For genes with two primer sets, fold
changes represent the mean result for both primer sets. Microarray analysis was
performed as described previously (36), with three transgenic and three control
E16.5 placental samples.
In situ hybridization and histological and immunohistochemical analyses.
Placentas were fixed overnight in phosphate-buffered 4% paraformaldehyde
(PFA) and paraffin embedded, and 10-m sections were taken. Hematoxylin-
and-eosin (H&E) staining, riboprobe preparation, and in situ hybridizations
were performed as described previously (29). Cdkn1c cDNA was prepared as
described previously (29), Ascl2 was obtained from Azim Surani, Prl3d and
Prl3b1 cDNAs were obtained from Louis Lefebvre, Flk-1 was subcloned from a
cDNA gifted by David Bates, and Gcm1 and Hand1 cDNAs were obtained from
Takahiro Arima. A 546-bp Phlda2 cDNA fragment was cloned using primers
5-ACAGCCTGTTCCAGGTATGG-3 and 5-GGTTGGAAGCAGGTAACC
AA-3, and an 858-bp Slc22a18 cDNA was cloned using primers 5-AGAGCG
GCACTCTCACTCTC-3 and 5-GGTCAATGGTTGCACAGATG-3. Immu-
nohistochemistry was as described previously (21). For periodic acid-Schiff
(PAS) staining slides were deparaffinized, rehydrated, and treated with 1%
(wt/vol) periodic acid (Sigma) in distilled H2O for 5 min at room temperature.
Slides were washed in running water, incubated in Schiff’s reagent (Sigma) for 10
min at room temperature, rinsed in running tap water, counterstained with Gill’s
no. 3 hematoxylin (Sigma), dehydrated, and mounted by reversing the rehydra-
tion steps.
Cell proliferation by BrdU incorporation. Pregnant females were injected with
100 g/g bromodeoxyuridine (BrdU; Amersham) 3 h before dissection of em-
bryos. Placentas were fixed for 2 h in 4% PFA at 4°C and paraffin embedded, and
5-m sections were prepared. Slides were dewaxed in xylene and rehydrated
through graded ethanols, submerged in 1 citrate buffer (LabVision), and
heated at full power in a microwave for 15 min. Slides were cooled and blocked
for 20 min in Peroxidase Block (Envsion) and 30 min in 1% bovine serum
albumin (BSA) in phosphate-buffered saline (PBS). Slides were incubated over-
night at 4°C with anti-BrdU antibody (BD) diluted 1:150 in 1% BSA in PBS.
Antibody solution was washed off in PBS, and slides were incubated with horse-
radish peroxidase-labeled polymer (Envision) for 1 h at room temperature. A
3,3-diaminobenzidine chromogen and substrate mixture was applied to the
slides and allowed to develop for 10 min. Slides were counterstained in Mayer’s
hemalum, dehydrated, cleared, and mounted in DPX mounting medium.
Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end label-
ing (TUNEL) assay. Apoptosis was examined on midline paraffin-embedded
placenta sections at E10.5 and E12.5 using the DeadEnd Colorimetric TUNEL
system (Promega) according to the manufacturer’s instructions.
Biochemical determination of placental glycogen concentration. Glycogen was
extracted from whole placenta according to the method of Lo et al. (34) and
resuspended in 1 ml of H2O. Glycogen extract was diluted 1:60 in H2O, and the
glycogen concentration was determined using a glycogen assay kit (BioAssay
Systems) according to the manufacturer’s instructions.
Statistical analyses. Statistical significance (probability values) was deter-
mined using the Student t test (two-tailed distribution and two-sample unequal
variance) or the Mann-Whitney U test. The significance of the difference in
observed over the expected appearance of a particular genotype was determined
using the chi-square test.
RESULTS
A twofold increase in Phlda2 expression produces maximal
placental stunting. In our previous study three copies of a mod-
ified BAC transgene which spanned two intact genes, Phlda2 and
Slc22a18 (Fig. 1A), caused a severe placental growth restriction
phenotype (46). Phlda2 and Slc22a18 transcript levels did not
correlate with the number of transgene copies, suggesting that
the phenotype might be due to highly misregulated expression.
Breeding this three-copy line for a further eight generations
into the 129/Sv genetic background stabilized the expression of
Phlda2 and Slc22a18 to approximately 4 times the endogenous
level at E12.5 and E16.5 (Fig. 1B). Similar results were obtained
in a mixed 129/Sv  C57BL/6 background (Fig. 1B). A newly
generated line, 10-10, carrying the same modified transgene ex-
pressed Phlda2 at 2.8 times and Slc22a18 at 1.8 times the wild-
type levels, and a third line 5D3, which carried a single copy of an
unmodified version of the BAC transgene (2), expressed Phlda2
and Slc22a18 at 2.3 and 1.6 times the wild-type levels, respectively
(Fig. 1B). The Cdkn1c placental enhancers are not encompassed
by the BAC (20, 29), and Cdkn1c was not expressed from the
transgene in the placenta in any line (Fig. 1B), thus uniquely
isolating the consequences of excess Phlda2 and Slc22a18 in the
placenta.
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FIG. 1. Increasing dosages of Phlda2 and Slc22a18 with precise temporal and spatial expression. (A) Schematic of the BAC transgene. The top
line is a genomic map of the IC2 region on distal mouse chromosome 7. The hatched region marks KvDMR1, which is methylated only on the
maternal allele. Arrows indicate the direction of transcription. Below is a map of the 85-kb transgene (BAC144D14). Filled boxes show the
positions of the intact genes. In addition to Phlda2, Slc22a18, and Cdkn1c, the transgene includes the 3 untranslated region (UTR) of Napl14
(white box) but not the 5 untranslated region. The modified BAC used to generate lines 10-15 and 10-10 has a -galactosidase-neomycin (geo)
fusion gene inserted into Cdkn1c, indicated by the arrow and filled box. (B) Placental QRT-PCR results for Phlda2 (top), Slc22a18 (middle), and
Cdkn1c (bottom). Data at E12.5 and E16.5 from the three-copy line 10-15 in a pure 129/Sv (99% 129/Sv) or a mixed (129/Sv  C57BL/6) genetic
background demonstrates the stabilization of expression of Phlda2 and Slc22a18 to approximately 4 times the endogenous level. Data from the
single-copy line 5D3 and the newly generated line 10-10 in a mixed genetic background at E12.5 demonstrate approximately two- and threefold
increased expression of Phlda2 and Slc22a18. Consistent with the absence of Cdkn1c placental enhancers on the transgene, Cdkn1c expression was
comparable in wild-type (WT) and transgenic placentas in all three lines. (C) In situ hybridization with a Phlda2 riboprobe reveals similar spatial
localizations of mRNA in control and transgenic 10-15129/Sv placentas at E10.5 and E12.5. (D) In situ hybridization with a Slc22a18 riboprobe
reveals similar spatial localizations of mRNA in control and transgenic 10-15129/Sv placentas at E12.5. (E) Localization of Phlda2 protein at E10.5,
E12.5, and E16.5 in both control and transgenic placentas with a similar pattern. Scale bar, 200 m (4 magnification). (F) Phlda2 protein
localization at 40 magnification. Asterisks indicate the large but inconspicuous type I trophoblast cells lining the maternal vessels, which are not
stained and do not express Phlda2 in either wild-type or transgenic samples. Plus signs indicate the Phlda2-positive clusters of type II cells in the
middle layer of the trilaminar trophoblast, and the type III trophoblast cells lining the fetal vessels (not marked) are weakly positive for Phlda2.
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Phlda2 and Slc22a18 mRNAs were similarly localized to the
labyrinth in control and transgenic placentas, with increased
signal intensity in transgenic placentas reflecting the increased
dosage of both genes (Fig. 1C and D). The spatial distribution
of the Phlda2 mRNA partially mirrored that of Slc22a18, sug-
gesting that they may share enhancers which, unlike the pla-
cental enhancers for Cdkn1c, were present within the trans-
gene. The Phlda2 protein in the transgenic placentas correctly
localized to the ectoplacental cone (Fig. 1E) and specifically to
type II (strong staining) and type III (weak staining) tropho-
blast cells in the trilaminar labyrinthine layer (Fig. 1E and F).
Type I trophoblast cells were Phlda2 negative in both the
control and the transgenic placentas (Fig. 1F), demonstrating
that the BAC transgene recapitulated both the gross and the
microscopic Phlda2 expression profiles. This allelic series is
therefore a useful tool for defining the phenotypic conse-
quences of increasing the dosage of Phlda2 and Slc22a18 from
the normal single dose to approximately two (line 5D3), three
(line 10-10), and four (line 10-15) doses while maintaining the
correct spatial and temporal pattern of expression of these
genes in the placenta.
In our previous study transgenic placentas with 10-fold
overexpression of Phlda2 and Slc22a18 were 25% and 17%
lighter at E14.5 and E16.5, respectively. We examined placen-
tal wet weights in the pure 129/Sv background, where expres-
sion was 4 times the endogenous level from E12.5 to E18.5
(Fig. 2A). Transgenic placentas were 15.4% lighter than wild-
type placentas at E12.5, and the difference increased to a maximal
26.2% at E13.5. Wild-type placentas reached their maximum
weight at E14.5, exhibiting an increase of approximately 50%
between E12.5 and E14.5, with the majority of this weight gain
occurring from E13.5. Wild-type placental weight did not sig-
nificantly alter between E14.5 and E18.5, but the weight of
transgenic placentas increased by approximately 10% between
E16.5 and E18.5 such that the weight difference at E18.5 (9%)
was considerably less than at E14.5 (15%).
In order to make a precise comparison of placental stunt-
ing between 10-15129/Sv and the other transgenic lines that
were not in the 129/Sv background, we first sorted to exclude
the possibility of strain differences in the severity of placen-
tal stunting by examining placental weights in a mixed ge-
netic background (129/Sv  C57BL/6). The overall weights
of both the wild-type and 10-15 transgenic placentas were
greater in the mixed background than in the pure 129/Sv
background, but the degrees of stunting were similar (Fig.
2B). Lines 10-10Mixed and 5D3Mixed were stunted to similar
extents (Fig. 2B; see Table S1 in the supplemental material).
Thus, a single extra dose of the transgene was sufficient to
induce the severest placental stunting, and normalizing the
Phlda2 dosage in this single-copy line by introducing a tar-
geted deletion of the maternal Phlda2 allele restored pla-
cental weights to the range of the wild type (106.0  15.9
versus 96.8  13.8 mg; wild type 	 53, Phlda2/ plus
5D3 	 52; P 	 0.002), excluding a major role for Slc22a18
in placental stunting (Fig. 2C).
Reduction in placental weight reflects a specific loss of the
junctional zone. Kvdmr1/ mice, which overexpress Phlda2 in
addition to Cdkn1c, Ascl2, and five other genes, exhibit a re-
duction in the junctional zone to labyrinth ratio at E14.5.
Histological examination revealed a similar deficiency of the
junctional zone in line 10-15129/Sv (Fig. 2D). There was a 2.3-
fold reduction in the volume ratio of the junctional zone to the
labyrinth at E14.5 (0.37  0.056 versus 0.16  0.025; P 	
0.029) (see Table S2 in the supplemental material). The vol-
ume ratio was similar to the area ratio when measurements
were made at the placental midline at E14.5 (2.4-fold reduc-
tion; 0.38  0.13 versus 0.16  0.05; P 	 4.4  104) (Fig. 2C;
see Table S2 in the supplemental material) and at E16.5 (2.4-
fold reduction; 0.28 0.06 versus 0.12 0.04; three litters; n	
21; P 	 5.67  106) (see Table S2 in the supplemental
material). Consistent with the weight data the area of junc-
tional zone loss was comparable (60% of the wild-type area) in
the mixed genetic background for all three lines at E14.5 with
no significant loss of the labyrinth zone (Fig. 2E and F; see
Table S2 in the supplemental material).
Strain differences in the ratio of the junctional zone to the
labyrinth zone. We noted an absolute difference in placental
wet weight between pure wild-type 129/Sv placentas and those
from the 129/Sv  C57BL/6 cross, with the later being 38%
heavier at E14.5 (78.7  12.5 versus 108.6  9.2 mg; wild-type
placentas from 19 litters; n 	 73; P 	 2.10  1018) and 45%
heavier at E18.5 (79.6  6.9 versus 115.4  7.2 mg; wild-type
placentas from 22 litters; n 	 82; P 	 7.22  1037). The
increased weight of placentas in a mixed genetic background
appeared to be due entirely to the presence of a greater junc-
tional zone area, which was 2.34 times greater in placentas in
the mixed genetic background than in those in the 129/Sv
background (1.36  0.40 versus 3.17  0.61 mm2; wild-type
placentas from 11 litters; n	 37; P	 3.29 106). In contrast,
there was no significant difference in the area of the labyrinth
region (3.66  0.36 versus 3.85  0.79 mm2; P 	 0.104). The
difference in the combined area of the junctional zone and
labyrinth region was comparable to the weight difference be-
tween the two genetic backgrounds, with a 37% increased area
in mixed genetic background placentas (5.10  0.41 versus
7.00  1.04 mm2; P 	 7.17  105).
Phlda2 limits glycogen storage and drives a progressive mis-
localization of Tpbpa-positive cells into the labyrinth. The dis-
tribution of glycogen was studied by PAS staining. PAS-posi-
tive cells were observed in the junctional zone at E12.5 in both
control and transgenic placentas, but staining was markedly
reduced at this time point and throughout gestation in the
transgenic placenta (Fig. 3A), the reciprocal of Phlda2 defi-
ciency. We also noted a second critical difference in glycogen
staining. While the glycogen cells of wild-type placentas pre-
dominantly appeared to have migrated into the maternal de-
cidua at E16.5, glycogen staining of transgenic placentas per-
sisted in the junctional zone. A biochemical determination of
glycogen was performed at E14.5 for line 10-15 in the 129/Sv
and C57BL/6 backgrounds and for the single-copy line 5D3,
which revealed a 25 to 35% loss of stored glycogen (Fig. 3B).
In situ hybridization for the ectoplacental cone and junc-
tional zone marker Tpbpa (33) revealed a second mislocal-
ization defect (Fig. 3C). Tpbpa staining was correctly local-
ized to cells of the ectoplacental cone at E10.5 although
staining was markedly reduced. A similar reduction in signal
was observed at E12.5, with the junctional zone appearing as
a more compact region in transgenic placentas. At E18.5 the
junctional zone appeared as a distinct zone in wild-type
placentas, with a clear boundary existing between this and
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the labyrinth region. In transgenic placentas, however, this
boundary between the two zones was completely absent,
with only a few Tpbpa-positive cells localized in the anticipated
area. The majority of Tpbpa-positive cells were instead dispersed
throughout the labyrinth region of transgenic placentas (Fig. 3C).
Excluding a role for Slc22a18 in regulating glycogen storage.
The junctional zone was restored by normalizing the Phlda2
dosage in the KvDMR1/ placenta (46). In a similar experi-
ment using our single-copy BAC transgenic line, we addition-
ally rescued the mislocalization defects and returned glycogen
FIG. 2. A double dose of Phlda2 induces the maximal reduction in the junctional zone irrespective of the genetic background. (A) Pla-
cental wet weights for the three-copy transgenic line 10-15 in a pure 129/Sv genetic background (see Table S1 in the supplemental material).
Light blue columns, 10-15129/Sv transgenics. (B) Placental wet weights in a mixed (129/Sv  C57BL/6) genetic background. Line 10-15, line
10-10, and line 5D3 transgenic placentas show similar degrees of placental stunting at E14.5 (and E18.5; see Table S2 in the supplemental
material). (C) Placental wet weights in a C57BL/6 genetic background for single-copy line 5D3, Phlda2/ null, and double-transgenic (5D3
and Phlda2/) placentas. (D) H&E staining for the three-copy transgenic line 10-15129/Sv from E10.5 to E18.5 illustrating a progressive loss
of the junctional zone. Jz, junctional zone; Lab, labyrinth; Dec, maternal decidua. Scale bar, 500 m. (E) H&E staining for the single-copy
transgenic line 5D3Mixed at E14.5 illustrating a similar restriction of the junctional zone. Scale bar, 500 m. (F) Junctional zone and labyrinth
areas at the placental midline at E14.5. The line 10-15129/Sv (three copy, filled columns) mean junctional zone area of transgenic placentas
is 59.9% less than the wild-type (WT) area with no significant effect on labyrinth area and a combined area reduction of 19%. Data for the
mixed background are shown below. The line 10-15Mixed (dark blue columns) junctional zone area is 57% of the wild-type area with no
significant effect on the labyrinth area and a combined area reduction of 21%. The line 10-10Mixed (purple columns) junctional zone area
is 54.9% of the wild-type area with no significant effect on the labyrinth area and a combined area reduction of 25%. The line 5D3Mixed (single
copy, green columns) junctional zone area is 60% less with no significant effect on the labyrinth area and a combined area reduction of 30%
(see Table S2 in the supplemental material).
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staining to within the normal range (Fig. 4A and B), formally
excluding a major role for Slc22a18 in these phenotypes.
Phlda2 alters the ratio between spongiotrophoblast and gly-
cogen cells in the junctional zone. Marker gene analysis was
performed for Ascl2 to reveal characteristic expression in the
ectoplacental cone, spongiotrophoblast, and labyrinthine tro-
phoblast similarly distributed in both control and transgenic
mouse placentas, but at a lower intensity in the transgenics
(Fig. 5A). Expression of the gene for heart and neural crest
derivatives expressed transcript 1 (Hand1), which is essential
for giant trophoblast cell differentiation (44), was similar in
control and transgenic placentas (Fig. 5B), as was that of the
gene for glial cell missing 1 (Gcm1) (Fig. 5C), which marks
branching of the labyrinth (3). The relative abundance of giant
cells was examined with the genes for giant-cell-specific probes
placental lactogen I (Prl3d) and placental lactogen II (Prl3b1)
(Fig. 5D). Prl3d is expressed in the giant cell border, and Prl3b1
is exclusively expressed in the trophoblast giant cell layer be-
ginning around E9.5 and then later in all layers of the placenta
(28). These markers showed similar distributions and intensi-
ties in the control and experimental placentas, suggesting no
overt defect effect in giant trophoblast cells. Cdkn1c (Fig. 5E),
FIG. 3. Mislocalization defects revealed by PAS staining and in situ hybridization analysis of Tpbpa. (A) PAS staining of midline placental
sections from E10.5 to E18.5 reveals reduced glycogen staining in the transgenic junctional zone until E16.5. Glycogen staining locates to the
maternal decidua in control placenta but not transgenic placenta at E16.5, as indicated by the black arrow. Scale bar, 100 m. (B) Direct
biochemical determination of stored glycogen at E14.5 shown as a percentage of wild-type (WT) values. Actual values: 10-15129/Sv, 5.13  1.37
versus 3.92 0.99 mg/g placenta (n	 25, P	 0.0148); 10-15Mixed, 8.92 2.12 versus 6.13 1.62 mg/g placenta (n	 30, P	 3.28 104); 5D3BL6,
11.44  2.37 versus 7.39  1.27 mg/g placenta (n 	 29, P 	 5.96  1010). (C) Hybridization of adjacent midline placental sections from E10.5
to E18.5 with the junctional zone antisense riboprobe Tpbpa. Mislocalized patches of Tpbpa-positive cells within the labyrinth are indicated by the
black arrow. Scale bar, 200 m.
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which is expressed in the ectoplacental cone, in giant tropho-
blast cells (44), and transiently in glycogen cells (23), was
distributed normally, as was the gene for the kinase insert
domain protein receptor (Flk1/Kdr), which marks the fetal
vasculature and plays a key role in vascular development (48)
(Fig. 5F). These data indicate that the placental defect was
confined to cells contributing to the junctional zone and not
labyrinthine trophoblast cells or giant cells. Quantitation of
mRNAs performed at E12.5 and E16.5 revealed a significant
reduction in Ascl2 and Tpbpa at both time points, consistent
with a specific loss of the junctional zone (Fig. 5G; Table 1).
The subtle differences in the expression levels of Flk1 and the
gene for FMS-like tyrosine kinase 1 (Flt1) likely reflected their
differential expression in the labyrinth and junctional zone,
respectively (6). Gcm1 was also increased reflecting the change
in ratio between the labyrinth and the junctional zone. Igf2,
insulin-like growth factor 1 receptor (Igf1r), and insulin-like
growth factor 2 receptor (Igf2r) gene expression levels were
unchanged, suggesting a balanced Igf2 signaling pathway (Ta-
ble 1).
Two major cell types originate from the ectoplacental cone,
the spongiotrophoblast and the glycogen cells. The glycogen
cell population undergoes a dramatic 80-fold expansion from
approximately 2,000 cells at E12.5 to 1.4 million cells at E14.5,
whereas spongiotrophoblast cells undergo their major prolif-
erative event prior to E12.5, at which time point nearly 2
million cells are present occupying the bulk of the junctional
zone (9). The marked reduction in Tpbpa and Ascl2 staining
demonstrated that the phenotype was already well established
at E10.5. Both proliferation (BrdU incorporation) and apop-
tosis (TUNEL) were relatively unchanged at E10.5 and E12.5
(see Fig. S1 in the supplemental material), also suggestive of
an earlier defect. Markers specific to the spongiotrophoblast
and glycogen cell populations were quantified at E12.5 and
E16.5. The gene for prolactin family 8 subfamily A member 8
(Prl8a8), which is expressed specifically in spongiotrophoblast
cells (50), was markedly reduced at both time points (Fig. 5G;
Table 1). In contrast, there was only a small reduction in the
expression of the gene for gap junction protein beta 3 (Gjb3/
Cx31) and no difference in the expression of the gene for
protocadherin 12 (Pcdh12). Both of these genes are expressed
exclusively in the glycogen cells of the mouse placenta (5, 60).
The relatively normal expression of Gjb3 and Pcdh12 sug-
gested that Phlda2 did not limit expansion of the glycogen cell
population. The expression of the genes for several enzymes
critical for glycogen metabolism, including those for glycogenin
(Gyg), glycogen synthases 1 and 2 (Gys1 and -2), UDP-glucose
pyrophosphorylase (Ugp2), and 1,4-
-glucan branching en-
zyme (Gbe1), was also comparable to wild-type expression
(Fig. 5G; Table 1). The marked reduction in stored glycogen
appeared to originate not from a loss of glycogen cells but from
a change in the microenvironment provided by the spongio-
trophoblast cells.
Altered expression of placental nutrient transporters. A re-
duction in stored glycogen could occur as a result of reduced
glucose transport, but expression of the genes for two placental
glucose transporters, solute carrier family 2 (facilitated glucose
transporter) members 1 (Slc2a1) and 3 (Slc2a3), was in fact
higher in the transgenic placentas (Table 2). Upregulation of
Slc2a3 has previously been reported in a mouse model in which
the placenta-specific Igf2 promoter has been deleted, causing
early placental growth restriction and late embryonic growth
restriction (12). In contrast to the Igf2 P0/ model, no signif-
icant effect on the expression level of Slc38a4 was detected
although six other nutrient transporters were significantly up-
regulated in Phlda2 transgenic placentas (Table 2), which may
FIG. 4. Slc22a18 does not regulate glycogen storage. (A) In situ
hybridization of Tpbpa to control (wild type [WT]), Phlda2-deficient
(Phlda2/), single-copy BAC transgenic (5D3), and double-trans-
genic (Phlda2/ plus 5D3) placentas at E14.5 illustrating restoration
of the junctional zone. Tpbpa staining within the labyrinth occurs in the
5D3 transgenic placentas but is infrequent in wild-type and double-
transgenic placentas, indicating a rescue of this defect. Scale bar, 500
m. (B) PAS staining of the four genotypes at E14.5 and E18.5 dem-
onstrates restoration of glycogen levels. Mislocalized cells in the 5D3
labyrinth, indicated by the black arrow, are absent in double transgen-
ics. Scale bar, 200 m.
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suggest that compensatory mechanisms are triggered in order
to overcome the junctional zone deficit.
No evidence of embryonic lethality. A complete loss of the
junctional zone is embryonic lethal (26). For line 10-15129/Sv,
the number of wild-type and transgenic conceptuses observed
at each developmental stage was compared to the number that
would be expected according to Mendelian ratios using the
chi-square (2) test. P values for each analysis are shown in
Table 3. Wild-type and transgenic conceptuses were observed
at the anticipated Mendelian ratios up to E18.5, indicating that
a 60% loss of the junctional zone was compatible with survival.
Progressive slowdown of embryonic growth. In our previous
study transgenic embryos from the three-copy line 10-15 were
indistinguishable from control littermates at E14.5 but 10%
lighter at E16.5 with marginal statistical significance. Similarly,
transgenic embryos in the pure 129/Sv genetic background
FIG. 5. In situ hybridization of placental marker genes. (A) Ascl2 expression at E10.5 and E12.5. Spatially appropriate but reduced intensity
of Ascl2 signal in transgenic placentas. Scale bar, 200 m. (B) Hand1 and (C) Gcm1 at E10.5 and E12.5 showing spatially appropriate localization
with similar intensity in transgenic placentas. Scale bar, 200 m. (D) Relative abundance of giant cells examined by hybridization of midline
placental sections with giant-cell-specific probes. Prl3d at E10.5 and Prl3b1 at E12.5, E14.5, and E16.5. Scale bar, 500 m. (E) Spatially appropriate
Cdkn1c expression at E12.5 and (F) Flk1 expression at E10.5. Scale bar, 100 m. (G) Relative expression levels of critical developmental genes
in 10-15129/Sv and wild-type (WT) placentas at E12.5 and E16.5 expressed as relative fold change.
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weighed the same as wild-type embryos at E14.5 but weighed
6.6% less at E16.5 (P 	 1.39  103) and 13.2% less at E18.5
(P 	 8.66  1015) (Fig. 6A). Growth restriction was less
apparent in the mixed genetic background. At E18.5, 10-
15Mixed transgenic embryos weighed 4.4% less than wild-type
embryos (P 	 0.0278) and 10-10Mixed embryos weighed 5.6%
less (P 	 0.0089) (Fig. 6B). As observed for placental weights,
wild-type embryos were significantly heavier in the mixed ge-
netic background in comparison to pure 129/Sv embryos at
both gestational stages examined, being 11.9% heavier at
E14.5 (222.5  35.4 versus 249.0  19.4 mg; wild-type weights
from 19 litters; n 	 73; P 	 1.13  104) and 8.5% heavier at
E18.5 (1,215.7  54.9 versus 1,318.6  60.7 mg; wild-type data
from 22 litters; n 	 82; P 	 6.57  1012). We were unable to
determine the relationship between the placental phenotype
and embryonic weight in the single-copy line due to the trans-
genic expression of Cdkn1c in the embryo in this line, which
carries the unmodified version of the BAC (2). However, in-
creasing Phlda2 and Slc22a18 from three to four doses did not
further decrease embryonic weight.
In summary, a single extra dose of Phlda2 had serious con-
sequences for placental development, driving the loss of the
junctional zone and a progressive mislocalization of cells from
TABLE 1. Placental marker gene expression analysisa
Gene
Mean fold change  SD (P value)
E12.5 E16.5
Gcm1 1.40  0.16 (0.014) 1.54  0.35 (0.014)
Hand1 1.25  0.37 (0.014) 1.25  0.13 (0.014)
Ascl2 1.55  0.25 (3.27  104) 5.51  1.02 (3.23  104)
Prl8a8 1.70  0.52 (4.40  104) 3.02  0.65 (4.40  104)
Tpbpa 2.07  0.17 (0.014) 2.50  0.51 (0.014)
Gjb3 1.17  0.15 (3.27  104) 1.14  0.16 (1.18  103)
Pcdh12 1.07  0.35 (0.369) 1.07  0.39 (1.0)
Gbe1 1.35  0.09 (0.014) 1.34  0.10 (0.014)
Gyg 1.21  0.09 (0.013) 1.52  0.50 (0.014)
Gys1 1.10  0.08 (0.219) 1.23  0.48 (1.0)
Gys2 1.71  0.47 (0.014) 1.23  0.48 (1.0)
Ugp2 1.50  0.30 (0.219) 1.01  0.10 (1.0)
Flk1 1.16  0.22 (0.219) 1.43  0.16 (0.014)
Flt1 2.06  0.14 (0.014) 3.01  0.84 (0.014)
Igf1 1.03  0.11 (0.487) 1.29  0.30 (0.219)
Igf1r 1.32  0.19 (0.027) 1.19  0.40 (1.0)
Igf2 1.07  0.09 (0.219) 1.13  0.16 (0.219)
Igf2r 1.16  0.12 (0.047) 1.06  0.33 (1.0)
a Relative changes in expression in transgenic placentas were determined by
QRT-PCR at E12.5 and E16.5. Statistical significance was determined by Mann-
Whitney test; n 	 4  4.
TABLE 2. Relative expression levels of genes encoding placental
transporters in transgenic placentas of line 10-15 micea
Gene Fold change(s)(microarray)
Fold change (QRT-PCR)
(P value)
Slc2a1 1.7b
Slc2a3 (2 probes) 1.7,b 2.9b 1.7  0.08 (0.014)
Slc3a2 1.5b 1.5  0.24 (0.014)
Slc19a2 2.0b
Slc22a3 2.5b
Scl25a3 1.7b
Slc38a2 2.0b 1.7  0.07 (0.037)
Slc38a4 1.3c 1.0  0.15 (1.00)
Slc40a1 2.1b
Slc41a1 1.7b
a Fold changes in transporter expression at E16.5 were determined by microar-
ray analysis. Transporters altered in a Igf2 P0/ model (12) were confirmed by
QRT-PCR on biological replicates at E16.5. Statistical significance was deter-
mined by Mann-Whitney test.
b P  0.05.
c No statistically significant difference.
TABLE 3. No embryonic lethality associated with the severe
placental defecta
Stage
No. of progeny
P value
(2)Wild type Transgenic
Observed Expected Observed Expected
E12.5 39 37 35 37 0.216
E13.5 18 19.5 23 19.5 0.610
E14.5 31 26.5 22 26.5 1.528
E16.5 30 29 28 29 0.069
E18.5 47 41.5 36 41.5 1.458
a The chi-square test was performed to determine if the observed frequencies
of wild-type and transgenic progeny at each stage during gestation differed
significantly from the expected frequency predicted by Mendelian inheritance.
FIG. 6. Slowdown of embryonic growth. (A) Weights of wild-type
and transgenic embryos of line 10-15129/Sv in a pure 129/Sv background
at the indicated gestational stages. Transgenic embryos show a 6.6%
reduction in wet weight at E16.5 (600.0  48.3 versus 560.5  40.3 mg;
8 litters; n 	 58; P 	 1.39  103) and a 13.2% reduction at E18.5
(1,215.7 54.9 versus 1,055.6 88.1 mg; 11 litters; n	 75; P	 8.66
1015). Error bars show standard deviations. (B) Weights of wild-type
and transgenic embryos of lines 10-15Mixed and 10-10Mixed in a mixed
(129/Sv  C57BL/6) genetic background at E18.5. 10-15Mixed trans-
genic embryos show a 4.4% reduction in wet weight (1,327.6  64.2
versus 1,269.1  86.9 mg; 6 litters; n 	 37; P 	 0.0278). 10-10Mixed
transgenic embryos are 5.6% lighter (1,322.9  57.7 versus 1,246.2 
79.9 mg; 4 litters; n 	 26; P 	 0.0089). Error bars show standard
deviations. Significance levels according to the Student t test are indi-
cated by asterisks as follows: *, P  0.05; *, P  0.01; ***, P  0.001.
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the junctional zone into the labyrinth. Excess Phlda2 also dra-
matically reduced the amount of stored glycogen, and the gly-
cogen cells additionally failed to mobilize into the maternal
decidua late in gestation. Despite this severely disorganized
placenta, embryos were viable and showed a loss of growth
potential only very late in gestation.
DISCUSSION
Previous data have suggested a pivotal role for the imprinted
gene Phlda2 as a growth rheostat in the murine placenta which
negatively regulates the expansion of the junctional zone in the
murine placenta (20, 46). Here we have shown that a single
extra dose of Phlda2 leads to a 60% loss of the junctional
zone with a dramatic 25 to 35% reduction in stored glyco-
gen, changes that are the reciprocal of those seen with Phlda2
deficiency. Uniquely, excess Phlda2 also causes a failure of
glycogen cells to migrate into the maternal decidua in a timely
manner. Instead, Tpbpa-positive cells progressively mislocalize
into the labyrinth, resulting in a complete collapse of the junc-
tional zone by E18.5. Interestingly, despite these severe pla-
cental defects, there is no loss of fetal viability. Instead, there
is a progressive slowing of embryonic growth culminating in a
13% decrease in embryonic weight by E18.5. This finding mod-
ifies our understanding of the biological function of the junc-
tional zone. Based on the clear observation of lethality in
Ascl2-deficient embryos (26), this zone is thought to be essen-
tial for the viability of the conceptus, but our data shown here
indicate that the junctional zone can be severely stunted and
yet remain fully able to support gestation. Thus, there is a
considerable reserve capacity in this zone making it a potential
drain on maternal resources and thus, according to the genomic
conflict model, a prime anatomical and genetic substrate for
imprinting.
Our BAC transgene spans two imprinted genes, Phlda2 and
Slc22a18, which we have shown were expressed in incremen-
tally increasing doses from 2 to 4 times the endogenous level in
the placenta and with the correct spatial and temporal pattern
in three transgenic lines. The maximal placental phenotype was
achieved by a single extra dose of the transgene, and geneti-
cally rescuing the dosage of Phlda2 excluded a significant role
for Slc22a18 in the identified placental phenotypes, assigning
them to Phlda2.
In mice there are four distinctive layers in the mature pla-
centa, the inner labyrinth layer, an intermediate junctional
zone, a layer of trophoblast giant cells, and the maternal de-
cidua. The Phlda2-induced phenotype was primarily apparent
at the junctional zone with a 60% loss of volume by E14.5 and
a complete breakdown of this zone by E18.5, while the laby-
rinthine and giant cell components remained relatively unal-
tered. A second major defect was the decrease in stored gly-
cogen evident as a reduction in the relative intensity of
glycogen staining and in the absolute quantity of stored glyco-
gen but not in the level of expression of Gjb3 and Pcdh12,
markers specific to the glycogen cell population, or the mRNAs
of several enzymes involved in the synthesis of glycogen, sug-
gesting that the proliferation and differentiation of this com-
ponent of the junctional zone were not affected by the altered
Phlda2 dosage. The marked reduction in Tpbpa and Ascl2
staining was already well established at E10.5, prior to the
80-fold expansion of the glycogen cell population that occurs
after E12.5, also suggesting the involvement of the second
major component of the junctional zone, the spongiotropho-
blast cells, which form the bulk of the junctional zone at E12.5
(9). Expression of Prl8a8, an mRNA specific to the spongio-
trophoblast cell type, was markedly reduced in transgenic pla-
centa at E12.5 and E16.5, indicative of the loss of this cell type.
These data demonstrate that Phlda2 negatively regulates the
pool of spongiotrophoblast cells in the placenta. Thus, the
ability of glycogen cells to store glycogen is determined by their
microenvironment. The simplest explanation is that spongio-
trophoblast cells are involved in the hormonal regulation of
glycogenesis. Indeed, the spongiotrophoblast layer is already
known to have a hormonal role providing pregnancy-related
hormones (9, 35). The failure of glycogen cells to migrate into
the maternal decidua and the progressive mislocalization of
Tpbpa-positive cells into the labyrinth suggest a cell adhesion
defect. This provides experimental evidence that spongiotro-
phoblast cells are also critical in maintaining the integrity of
the placental layers. Further studies are required to determine
whether these two roles are in some way coupled.
Glycogen cells are thought to provide a readily accessible
depot of glycogen that can be rapidly converted into glucose
(9). Depletion of these stores might have a consequence for
late embryonic growth. Consistent with this theory, we ob-
served a subtle, late intrauterine growth restriction in our
model. Several key placental transporters were upregulated in
the transgenic placenta. This expression profile is similar to
a confirmed model of placental insufficiency, the Igf2 P0/
mouse, suggesting an imbalance in the growth potential of the
embryo and the ability of the defective placenta to support late
embryonic growth in our model which is only partly overcome
by compensatory pathways (12). A role for Phlda2 in regulating
embryonic growth is also suggested by the finding that this
gene is overexpressed in placentas from human infants with
IUGR (36) and in term placentas from non-IUGR infants with
low birth weight (4). Although these data are consistent with a
role for increased dosage of Phlda2 in extrinsically limiting
embryonic growth, it is important to determine the contribu-
tion of excess embryonic expression of Phlda2 and Slc22a18 to
any embryonic phenotype.
Phlda2 deficiency causes placentomegaly with an expansion
of the junctional zone and increased glycogen (20). Imprinting
Phlda2 thus may have acted to increase glycogen stores, pro-
viding a rapidly mobilizable energy depot for the final stages of
gestation precisely when the fetus is placing the highest de-
mands on maternal resources for growth. The function of
Phlda2 protein at the cellular level is still under investigation,
but it is already known that this pleckstrin homology domain-
containing protein can bind phosphatidylinositide lipids, so it
may be acting in cell signaling or subcellular trafficking (47). As
has been suggested previously (20, 55), while the biochemical
functions of imprinted genes are diverse, these genes increas-
ingly appear to act in concert to precisely regulate fetal and
placental growth. A rationale for imprinting the adjacent Cdkn1c
locus based on the parental conflict theory is provided by its
role in negatively regulating embryonic growth. Excess expres-
sion of this maternally expressed gene restricts embryonic
growth, while loss of expression enhances embryonic growth, at
least at E13.5 (2). Embryos are not overgrown at birth (52, 57,
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59), suggesting that their growth potential is not maintained
later in gestation. These data could indicate that coimprinting
of Cdkn1c and Phlda2 is functionally significant with a reduced
dosage of Cdkn1c intrinsically enhancing embryonic growth
and a reduced dosage of Phlda2 supplying the necessary in-
crease in extraembryonic resources required to support this
growth potential late in gestation.
In the eutherian mammals studied so far the Kvdmr1 locus
controls the imprinting of both Cdkn1c and Phlda2 (17). The
physical linking of these genes predates the imprinting of this
locus (40). It is interesting, therefore, that Cdkn1c is bialleli-
cally expressed in marsupials (51), as is Phlda2 (S. Suzuki, M.
Renfree, and F. Ishino, personal communication), suggesting
that the IC2 domain acquired its imprinted status only after
eutherians diverged from marsupials. Little is known about
extraembryonic glycogen stores in marsupials, but there is
some evidence that a population of glycogenic cells may exist
within a chorioallantois-like structure of the Tasmanian bandi-
coot (18). Imprinting of the IC2 domain may have been instru-
mental in the transition from a relatively primitive internal
development in the common ancestor of marsupials and euth-
erians to the more complex placentation and more mature
internal development found in modern eutherians (see Fig. S2
in the supplemental material).
In summary, we have genetically demonstrated that Phlda2
regulates the storage of glycogen in the eutherian placenta.
Our data suggest that imprinting of this locus gave eutherians
an advantage by providing a depot of stored energy to support
the enhanced embryonic growth potential driven by imprinting
Cdkn1c.
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